Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study

OBJECTIVE: Programmed cell death 1 (PD-1) inhibitor has been in the market in China for several years, which lacks sufficient domestic evidence regarding its application in lung cancer. Thus, this study intended to assess the treatment outcome and tolerance of PD-1 inhibitor plus chemotherapy in adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Yang, Peng, Zhou, Xiao, Yang, Xuefeng, Wu, Shijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475215/
https://www.ncbi.nlm.nih.gov/pubmed/36117837
http://dx.doi.org/10.3389/fsurg.2022.954490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475215/
https://www.ncbi.nlm.nih.gov/pubmed/36117837
http://dx.doi.org/10.3389/fsurg.2022.954490

Ejemplares similares